Troy A. Ignelzi

CIK: 0001579829

Transaction Breakdown

Open Market Buys (P)3 (37.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (62.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RAPP

Rapport Therapeutics, Inc.

Officer

CTNM

Contineum Therapeutics, Inc.

Director

HRMY

Harmony Biosciences Holdings, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

RAPP
Rapport Therapeutics, Inc.
Oct 21, 2026
Purchase(P)
Direct
5.5K shares at avg. $26.10$144K
CTNM
Contineum Therapeutics, Inc.
Jun 26, 2026
Award(A)
Stock Option (right to buy)
Direct
19K shares-
HRMY
Harmony Biosciences Holdings, Inc.
Apr 2, 2026
Award(A)
Stock Option
Direct
17.7K shares-
RAPP
Rapport Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
148K shares-
CTNM
Contineum Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
14.8K shares-
RAPP
Rapport Therapeutics, Inc.
Mar 13, 2025
Purchase(P)
Direct
100 shares at avg. $9.98$998
RAPP
Rapport Therapeutics, Inc.
Mar 12, 2025
Purchase(P)
Direct
9.9K shares at avg. $10.10$100K
RAPP
Rapport Therapeutics, Inc.
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
142K shares-

		Type	Shares	Price		Ownership
Oct 21, 2026	RAPP Rapport Therapeutics, Inc.	Purchase(P)	5,500	$26.10	$143,550	Direct
Jun 26, 2026	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	19,000	-	-	Direct
Apr 2, 2026	HRMY Harmony Biosciences Holdings, Inc.	Award(A) Stock Option	17,710	-	-	Direct
Feb 2, 2026	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	148,000	-	-	Direct
Jun 26, 2025	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	14,750	-	-	Direct
Mar 13, 2025	RAPP Rapport Therapeutics, Inc.	Purchase(P)	100	$9.98	$998	Direct
Mar 12, 2025	RAPP Rapport Therapeutics, Inc.	Purchase(P)	9,900	$10.10	$99,990	Direct
Feb 3, 2025	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	142,000	-	-	Direct

1-8 of 8 transactions

About Ignelzi Troy A.

Ignelzi Troy A. (SEC CIK 0001579829) files insider reports with the SEC as Chief Financial Officer of Rapport Therapeutics, Inc. (RAPP), Director of Contineum Therapeutics, Inc. (CTNM) and Director of Harmony Biosciences Holdings, Inc. (HRMY).

Signal8 holds 8 ownership filings by Ignelzi Troy A. (1 Form 3, 7 Form 4), filed between Feb 4, 2025 and Oct 21, 2026. Those filings report 8 transactions, from Feb 3, 2025 to Oct 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ignelzi Troy A.'s filings is in BOSTON, MA.

Recent filings by Ignelzi Troy A.

Oct 21, 2026: Open-market purchase of RAPP shares (Form 4, code P).
Jun 26, 2026: Grant or award of CTNM derivative securities (Form 4, code A).
Apr 2, 2026: Grant or award of HRMY derivative securities (Form 4, code A).
Feb 2, 2026: Grant or award of RAPP derivative securities (Form 4, code A).
Jun 26, 2025: Grant or award of CTNM derivative securities (Form 4, code A).

Other insiders filing for Rapport Therapeutics, Inc. (RAPP)

HEALY JAMES, Director
Ceesay Abraham, Chief Executive Officer
Sanchez Ramiro, Director
Silva Paul M, Director
Young Wendy B., Director
PAUL STEVEN M, Director

How to read Form 4 transaction codes